The UK's National Health Service (NHS) is set to launch a groundbreaking trial involving over 20,000 patients across 200 general practitioner (GP) surgeries in England. The initiative, named STRIDE-RCT, aims to evaluate whether advanced blood tests can detect early signs of several common cancers, including prostate, ovarian, bowel, pancreatic, stomach, and liver cancers. Developed by the University of Birmingham, the tests will analyze blood samples for specific biomarkers that indicate potential cancer presence or rule out the disease. Four companies are participating in the trial: Proteotype (Enlighten test), Pinpoint AI (PinPoint test), Natera (Signatera test), and Mercy Bioanalytics (Halo test). Each test uses different methodologies to detect cancer signals. The Enlighten test identifies patterns of amino acid biomarkers in plasma to detect breast, bowel, lung, or prostate cancer. The Pinpoint AI test analyzes 32 biomarkers simultaneously, providing a color-coded risk assessment (red for high risk, amber for average, green for low risk). The Signatera test, already used for detecting cancer recurrence, relies on circulating tumor DNA fragments. The Halo test examines single extracellular vesicles that circulate at high levels even in early-stage cancer. Eligibility for the trial includes individuals aged 45 and over with abdominal symptoms such as persistent bloating or discomfort. The Department of Health highlighted that approximately 71,000 people are diagnosed annually with abdominal cancers in England, with nearly 35,000 deaths. Health Secretary Yvette Cooper emphasized that earlier diagnosis significantly improves treatment success rates and saves lives. Professor Peter Johnson described the trial as a 'revolution in cancer diagnosis,' while Cancer Research UK's Michelle Mitchell called it an important step toward helping GPs determine the need for further testing. The trial represents a significant advancement in non-invasive cancer screening, potentially reducing unnecessary hospital referrals and enabling earlier intervention.

The NHS in England is set to introduce a new trial involving multi-cancer blood tests in approximately 200 general practitioner (GP) surgeries. The initiative, led by the University of Birmingham and funded by the government, aims to detect abdominal cancers such as liver, ovarian, and pancreatic cancer at earlier stages, when they are often harder to diagnose. These cancers frequently present with vague symptoms that can be mistaken for less serious conditions, leading to delayed diagnosis and poorer outcomes. The blood tests work by identifying specific proteins or DNA fragments in the blood that may indicate the presence of cancer. Patients aged 45 and over with symptoms like persistent pain or bloating will be eligible for the trial, which will involve over 20,000 participants. The tests are not designed to provide a definitive diagnosis but to help GPs determine which patients require further investigation. This trial follows a previous NHS trial of the Galleri test, which did not meet its primary goal of reducing late-stage cancer diagnoses but is still under review for potential benefits. NHS England's national clinical director for cancer, Prof Peter Johnson, highlighted the challenges of early detection for abdominal cancers, noting that symptoms are often misinterpreted. Early diagnosis is crucial for improving survival rates, as nearly 35,000 people in England die annually from cancers including pancreatic, stomach, liver, ovarian, and bowel cancer. The STRIDE-RCT trial will assess the accuracy of these blood tests for potential wider NHS use. Health Secretary Yvette Cooper expressed hope that such tests could expedite the identification of patients needing urgent care. Cancer Research UK's Michelle Mitchell supported the trial, stating it addresses a long-standing need for better tools to guide GPs in determining which patients require further testing. The trial will involve collecting blood samples during routine GP visits, with analysis conducted to detect cancer markers and potentially identify the cancer's origin within the body. A positive result does not confirm cancer, and a negative result does not guarantee the absence of cancer. The initiative represents a significant step towards improving early detection and treatment outcomes for hard-to-diagnose cancers.

Volume 14, Issue 16 | October 29, 2026

A large study tracking more than 316,000 adults for up to 15 years suggests that a routine blood test may reveal important clues about future dementia risk. A standard blood test taken during a...